期刊
DRUG DISCOVERY TODAY
卷 24, 期 10, 页码 2033-2043出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2019.07.007
关键词
-
资金
- Intramural Research Program at the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH) [ZIA MH002857]
- NARSAD Independent Investigator Award
- Brain and Behavior Mood Disorders Research Award
- NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002857, ZIAMH002927] Funding Source: NIH RePORTER
Recent research demonstrating that the glutamatergic modulator ketamine has rapid, robust, and sustained antidepressant effects has been a turning point in drug discovery for depression. The recent FDA approval of esketamine for adults with treatment-resistant major depressive disorder (MDD) has further underscored the relevance of this agent in spurring investigation into novel and mechanistically distinct agents for use in depression. Over the past two decades, ketamine research has ushered in a new wave of studies seeking to not only identify its mechanism of action but also to examine the antidepressant potential of novel or repurposed agents. This article reviews the approaches that have proven particularly fruitful for the field of neuropsychiatry.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据